How to invest in transformational innovation
UBS suggests investors focus on artificial intelligence, power infrastructure, and healthcare innovation for long-term growth potential amid market volatility. The research report highlights three key investment themes anticipated to shape equity market performance in the years ahead: AI, power and resources, and longevity.
AI-related capital spending is expected to surge to $1 trillion in 2026 and $1.4 trillion in 2027, fueled by continued investment from major tech firms and the growing deployment of autonomous AI agents. However, the rapid valuations and concerns over U.S. policy shifts and varying corporate performance have heightened risks for concentrated investments.
To mitigate this, UBS advocates for a diversified approach across the AI supply chain, encompassing selected semiconductor makers, hardware providers, prominent technology enterprises, and more stable industry segments.
Power infrastructure emerges as another promising long-term prospect due to the escalating demand for electricity driven by data center expansion. By 2030, annual investments in power and grid infrastructure are projected to reach $3 trillion, presenting opportunities in renewable energy, nuclear power, grid resilience, industrial automation, and essential minerals.
With data centers projected to consume 9% of U.S. electricity by 2035, up from around 4% currently, the sector's long-term outlook remains robust. Nevertheless, policy adjustments, project delays, and execution risks could introduce volatility. Nevertheless, strong order backlogs and investment pipelines bolster the sector's outlook for the future.
Healthcare innovation also stands as a third investment theme, with emphasis on treatments aimed at extending healthy lifespans. The global longevity market is anticipated to reach $8 trillion in annual revenue by 2030, up from $5.3 trillion in 2023. Obesity-related drug revenues are expected to grow by approximately 12% annually through 2030, driven by enhanced patient access, expanded insurance coverage, and novel oral treatments.
Promising clinical trial results in cancer, neurological, and cardiometabolic conditions may further fuel investment. UBS advises integrating these structural growth themes into diversified equity portfolios rather than relying solely on individual companies.
Rewritten by urgent.news; may contain errors — check the original.